KYTHERA (NASDAQ: KYTH) is a biopharmaceutical company that focuses on developing and commercializing high-demand medical aesthetics products. We target large-scale global opportunities to develop innovative drugs and medical devices to treat under-addressed aesthetic complaints. We look for market segments with both motivated patients and motivated physicians. Our longer-term strategy is to leverage our biotechnology and aesthetics experience to aggressively expand our product portfolio and pipeline.
Sep 22, 2015
KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss
Aug 18, 2015
KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
Jun 9, 2015 at 2:00 PM PT
May 7, 2015 at 1:30 PM PT